FIRST AMENDMENT TO LEASE AGREEMENTLease Agreement • August 8th, 2016 • Bellicum Pharmaceuticals, Inc • Pharmaceutical preparations • Texas
WHEREAS, Landlord and Tenant are parties to that certain Lease Agreement originally entered into by and between Original Landlord and Tenant, dated as of May 6, 2015 (the "Lease"), pursuant to which Tenant currently leases certain premises containing approximately 26,817 square feet of Net Rentable Area (the "Original Leased Premises"), which consists of 25,304 square feet of Net Rentable Area of Manufacturing Space designated as Suite 500, 705 square feet of Net Rentable Area of Interior Mechanical Space on the fourth (4'h) floor, and 808 square feet of Net Rentable Area of Exterior Mechanical Space on the fifth (5th) floor, all in the building commonly known as Life Science Plaza, located at 2130 West Holcombe Boulevard, Houston, Texas (the "Building"), all as more particularly described in the Lease;
CONSULTING AGREEMENTConsulting Agreement • August 8th, 2016 • Bellicum Pharmaceuticals, Inc • Pharmaceutical preparations • Texas
This CONSULTING AGREEMENT (“Agreement”), dated effective as of May 18, 2016 (“Effective Date”) is by and between Bellicum Pharmaceuticals, Inc. a Delaware corporation (the “Company”), having an office at 2130 West Holcombe Boulevard, Suite 800, Houston, Texas 77030 (the “Company Premises”) and Kevin M. Slawin, M.D. (the “Advisor”). (The Company and Advisor are referred to individually as a “Party” and collectively as the “Parties”).
BELLICUM PHARMACEUTICALS, INC. SPONSORED RESEARCH AGREEMENT NO. 2Sponsored Research Agreement • August 8th, 2016 • Bellicum Pharmaceuticals, Inc • Pharmaceutical preparations
THIS SPONSORED RESEARCH AGREEMENT (the “Agreement”) is entered into and made and effective as of May 20, 2016 (“Effective Date”) by and between BELLICUM PHARMACEUTICALS, INC., with offices at 2130 West Holcombe Boulevard, Suite 800, Houston, Texas 77030, United States of America (“Sponsor”), and ACADEMISCH ZIEKENHUIS LEIDEN, also acting under the name Leiden University Medical Centre, with offices at Albinusdreef 2, 2333 ZA Leiden, The Netherlands (“Leiden”). Sponsor and Leiden are referred to herein collectively as the “Parties” or individually as a “Party.”
